Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Update

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) saw a large drop in short interest during the month of August. As of August 31st, there was short interest totaling 25,053 shares, a drop of 65.5% from the August 15th total of 72,693 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average trading volume of 17,420 shares, the short-interest ratio is currently 1.4 days.

Analyst Upgrades and Downgrades

Several analysts have weighed in on PHAR shares. Weiss Ratings reiterated a “sell (d)” rating on shares of Pharming Group in a research note on Friday, August 7th. Oppenheimer reaffirmed an “outperform” rating on shares of Pharming Group in a report on Thursday, July 30th. Zacks Research lowered Pharming Group from a “hold” rating to a “strong sell” rating in a research report on Friday, July 31st. HC Wainwright reiterated a “buy” rating and issued a $37.00 price target on shares of Pharming Group in a report on Monday. Finally, Canaccord Genuity Group raised their price target on shares of Pharming Group from $37.00 to $38.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Three analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Pharming Group has a consensus rating of “Hold” and a consensus price target of $38.67.

Pharming Group Stock Performance

Pharming Group stock traded down $0.39 during midday trading on Monday, hitting $10.82. 19,561 shares of the company were exchanged, compared to its average volume of 16,620. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.31 and a current ratio of 3.01. The firm has a market capitalization of $765.84 million, a PE ratio of 90.17 and a beta of 0.01. The business has a fifty day simple moving average of $12.00 and a two-hundred day simple moving average of $13.80. Pharming Group has a fifty-two week low of $9.62 and a fifty-two week high of $21.34.

Pharming Group (NASDAQ:PHAR) last posted its earnings results on Thursday, July 30th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($0.04). Pharming Group had a net margin of 2.51% and a return on equity of 3.40%. On average, sell-side analysts forecast that Pharming Group will post 0.25 earnings per share for the current year.

Pharming Group Company Profile

Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands, focused on developing and commercializing treatments for rare diseases. The company uses its expertise in protein replacement therapies and other biotechnology platforms to address conditions with limited treatment options.

Pharming’s principal product is Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause severe swelling.